Gene-Modified Cell Therapy to Target CD56 for Oncology is under clinical development by Alaunos Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Gene-Modified Cell Therapy to Target CD56 for Oncology’s likelihood of approval (LoA) and phase transition for Lung Adenocarcinoma took place on 25 Mar 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Gene-Modified Cell Therapy to Target CD56 for Oncology Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Gene-Modified Cell Therapy to Target CD56 for Oncology overview

Gene-modified cell therapy is under development for the treatment of solid tumors including neuroblastoma, small-cell lung cancer, gastrointestinal cancer, genitourinary cancer, metastatic colorectal cancer, non-small cell lung cancer, squamous non-small cell lung cancer, lung adenocarcinoma, endometrial cancer, pancreatic cancer, non-small cell lung cancer and cholangiocarcinoma, breast cancer, ovarian cancer, squamous non-small cell lung cancer and glioblastoma. The drug development is based on non viral integration technology platform (Sleeping Beauty Transposon/Transposase System). It is administered through intravenous route.

Alaunos Therapeutics overview

Alaunos Therapeutics formerly ZIOPHARM Oncology, is a provider of next-generation immune therapies. The company offers Controlled IL-12 and t-cell therapy to fight blood cancers and solid tumors. Its Controlled IL-12 platform provides therapy for cold tumors by turning them hot by activating an immune response. The company also provides Sleeping Beauty, a clinically-advanced non-viral cell therapy technology which helps in the manufacturing of genetically modified chimeric antigen receptors (CARs) and T-cell receptors (TCRs) targeting specific tumor-derived antigens. Its products and technologies are used in the treatment of hematologic malignancies, solid tumors and graft-versus-host-disease. The company is headquartered in Boston, Massachusetts, the US.

Quick View Gene-Modified Cell Therapy to Target CD56 for Oncology LOA Data

Report Segments
  • Innovator
Drug Name
  • Gene-Modified Cell Therapy to Target CD56 for Oncology
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.